ArticleAlzheimer's & dementia (New York, N. Y.)

Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer's disease.

Philip Scheltens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.